Patents Expiring in December 2044
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | 11,878,022 | ⤷ Start Trial | Y | TREATMENT OF EDEMA IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | |||
| Novitium Pharma | INZIRQO | hydrochlorothiazide | FOR SUSPENSION;ORAL | 219141-001 | Jan 28, 2025 | RX | Yes | Yes | 11,878,022 | ⤷ Start Trial | Y | TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE | |||
| Springworks | GOMEKLI | mirdametinib | CAPSULE;ORAL | 219389-001 | Feb 11, 2025 | RX | Yes | No | 12,661,330 | ⤷ Start Trial | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION | ||||
| Springworks | GOMEKLI | mirdametinib | CAPSULE;ORAL | 219389-002 | Feb 11, 2025 | RX | Yes | Yes | 12,661,330 | ⤷ Start Trial | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION | ||||
| Springworks | GOMEKLI | mirdametinib | TABLET, FOR SUSPENSION;ORAL | 219379-001 | Feb 11, 2025 | RX | Yes | Yes | 12,661,330 | ⤷ Start Trial | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
